British health technology company, Visionable, has appointed David Walker to the newly-created position of chief commercial officer (CCO).
Visionable redesigns healthcare through a digital collaboration platform which enables clinicians to deliver better patient outcomes.
And the expansion of the business’ executive leadership team follows rapid growth in 2020, which saw £17m of investment that the company raised in Series A and Series A1 funding rounds.
Visionable has appointed Walker to capitalise on its existing success.
As the company’s first CCO, he will be responsible for developing and creating new partnerships with international organisations to expand Visionable’s presence in thriving markets.
He will also be identifying new markets where the company’s technology can make huge differences to current practices and efficiencies, also overseeing the expansion of the team as Visionable grows.
Walker has leadership experience in a range of industries, having held senior commercial roles at Sky Television, Dyson, fintech Neyber, and, most recently, as CCO of AI-based technology company, Winnow.
He said of the challenge: “I was drawn to Visionable because of the company’s clear dedication to its mission to make healthcare more equitable and accessible for all and its proposition that is changing healthcare as we know it: creating advanced, efficient systems that deliver better outcomes for both patients and professionals.
“Visionable is at an exciting phase of its development, experiencing exceptional demand, poised to scale up and with patented and unique technology to support its vision and I’m delighted to join the team and be involved in this next stage of the company’s growth.”
Chief executive and co-founder, Alan Lowe, added: “David has proved his ability, throughout a stellar career, to boost a company’s market share by selling value rather than price, a principle that is intrinsic to Visionable.
“I’m delighted to welcome him CCO to our expanding executive team and look forward to working closely with him as we forge partnerships and enter new markets to improve equity in healthcare and deliver better patient outcomes.”
